NRx Pharmaceuticals, Inc.
NRXP
$3.87
-$0.46-10.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.07M | 983.00K | 242.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.07M | 983.00K | 242.00K | -- | -- |
| Cost of Revenue | 631.00K | 408.00K | 97.00K | -- | -- |
| Gross Profit | 437.00K | 575.00K | 145.00K | -- | -- |
| SG&A Expenses | 3.81M | 4.57M | 2.81M | 2.74M | 2.94M |
| Depreciation & Amortization | 63.00K | 42.00K | 26.00K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.82M | 5.58M | 4.36M | 3.73M | 3.75M |
| Operating Income | -4.75M | -4.59M | -4.12M | -3.73M | -3.75M |
| Income Before Tax | -1.43M | 360.00K | -5.89M | -17.58M | -5.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.43M | 360.00K | -5.89M | -17.58M | -5.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.43M | 360.00K | -5.89M | -17.58M | -5.51M |
| EBIT | -4.75M | -4.59M | -4.12M | -3.73M | -3.75M |
| EBITDA | -4.69M | -4.55M | -4.11M | -3.73M | -3.75M |
| EPS Basic | -0.04 | 0.01 | -0.26 | -0.98 | -0.34 |
| Normalized Basic EPS | -0.03 | -0.08 | -0.13 | -0.42 | -0.17 |
| EPS Diluted | -0.04 | 0.01 | -0.26 | -0.98 | -0.34 |
| Normalized Diluted EPS | -0.03 | -0.08 | -0.13 | -0.42 | -0.17 |
| Average Basic Shares Outstanding | 32.33M | 28.96M | 22.23M | 17.93M | 16.41M |
| Average Diluted Shares Outstanding | 32.33M | 28.96M | 22.23M | 17.93M | 16.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |